• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会间皮瘤分期项目:即将发布的第九版胸膜间皮瘤 TNM 分类中“N”描述符的建议。
J Thorac Oncol. 2024 Sep;19(9):1326-1338. doi: 10.1016/j.jtho.2024.05.003. Epub 2024 May 9.
2
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会间皮瘤分期项目:即将发布的第九版胸膜间皮瘤 TNM 分类中“T”描述符修订建议。
J Thorac Oncol. 2024 Sep;19(9):1310-1325. doi: 10.1016/j.jtho.2024.03.007. Epub 2024 Mar 21.
3
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.国际肺癌研究协会胸膜间皮瘤分期项目:扩展数据库以提供第九版胸膜间皮瘤 TNM 分类修订信息。
J Thorac Oncol. 2024 Aug;19(8):1242-1252. doi: 10.1016/j.jtho.2024.01.018. Epub 2024 Feb 1.
4
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会间皮瘤分期项目:即将出版的第九版胸膜间皮瘤 TNM 分类中 M 描述符的建议。
J Thorac Oncol. 2024 Nov;19(11):1564-1577. doi: 10.1016/j.jtho.2024.08.022. Epub 2024 Aug 23.
5
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会胸膜间皮瘤分期项目:对即将出版的(第九版)胸膜间皮瘤 TNM 分类中 TNM 分期分组的修订建议。
J Thorac Oncol. 2024 Sep;19(9):1339-1351. doi: 10.1016/j.jtho.2024.05.002. Epub 2024 May 9.
6
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会间皮瘤分期项目:即将发布的第八版胸膜间皮瘤 TNM 分类中 N 描述符修订建议。
J Thorac Oncol. 2016 Dec;11(12):2100-2111. doi: 10.1016/j.jtho.2016.09.121. Epub 2016 Sep 26.
7
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目:即将出版的第九版肺癌 TNM 分类中 N 描述符修订建议。
J Thorac Oncol. 2024 May;19(5):766-785. doi: 10.1016/j.jtho.2023.10.012. Epub 2023 Oct 20.
8
The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会分期项目:数据库及对即将出版的第九版肺癌TNM分类中肺神经内分泌癌分期修订的建议。
J Thorac Oncol. 2025 Jan 24. doi: 10.1016/j.jtho.2025.01.013.
9
A randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma.一项关于培美曲塞维持治疗对比支持治疗在胸膜间皮瘤中的随机对照研究。 (你提供的原文中药物名称有误,正确的应该是培美曲塞,英文是pemetrexed ,而不是gemcitabine ,gemcitabine是吉西他滨 。我按照正确的信息进行了准确翻译,若你有特殊要求,请随时告知。)
Future Oncol. 2025 Jul;21(17):2203-2213. doi: 10.1080/14796694.2025.2516412. Epub 2025 Jun 12.
10
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.国际肺癌研究协会间皮瘤分期项目:M 描述符建议和即将发布的(第八版)间皮瘤 TNM 分类中 TNM 分期分组的修订。
J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. Epub 2016 Sep 28.

引用本文的文献

1
Pleural mesothelioma.胸膜间皮瘤
Nat Rev Dis Primers. 2025 Aug 7;11(1):56. doi: 10.1038/s41572-025-00640-3.
2
A Diagnostic Approach to Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的诊断方法
Pulm Ther. 2025 Jun 11. doi: 10.1007/s41030-025-00301-6.

本文引用的文献

1
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会间皮瘤分期项目:即将出版的第九版胸膜间皮瘤 TNM 分类中 M 描述符的建议。
J Thorac Oncol. 2024 Nov;19(11):1564-1577. doi: 10.1016/j.jtho.2024.08.022. Epub 2024 Aug 23.
2
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.国际肺癌研究协会胸膜间皮瘤分期项目:扩展数据库以提供第九版胸膜间皮瘤 TNM 分类修订信息。
J Thorac Oncol. 2024 Aug;19(8):1242-1252. doi: 10.1016/j.jtho.2024.01.018. Epub 2024 Feb 1.
3
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.一线纳武利尤单抗联合伊匹木单抗与化疗治疗不可切除恶性胸膜间皮瘤患者:CheckMate 743研究的3年结果
Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3.
4
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.一线纳武利尤单抗联合伊匹单抗治疗不可切除恶性胸膜间皮瘤(CheckMate 743):一项多中心、随机、开放标签、III 期临床试验。
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
5
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.放疗后恶性胸膜间皮瘤的外科治疗(SMART):来自单中心、2 期试验的最终结果。
Lancet Oncol. 2021 Feb;22(2):190-197. doi: 10.1016/S1470-2045(20)30606-9. Epub 2021 Jan 12.
6
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.间皮瘤:预防、诊断和治疗的科学线索。
CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8.
7
Endobronchial ultrasound-guided transbronchial needle aspiration mediastinal lymph node staging in malignant pleural mesothelioma.支气管内超声引导下经支气管针吸活检术用于恶性胸膜间皮瘤的纵隔淋巴结分期
J Thorac Dis. 2019 Feb;11(2):602-612. doi: 10.21037/jtd.2019.01.01.
8
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.美国间皮瘤:一项基于监测、流行病学及最终结果(SEER)-医疗保险的治疗模式与总生存情况调查。
Clin Epidemiol. 2016 Oct 26;8:743-750. doi: 10.2147/CLEP.S105396. eCollection 2016.
9
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.国际肺癌研究协会间皮瘤分期项目:即将发布的第八版胸膜间皮瘤 TNM 分类中 N 描述符修订建议。
J Thorac Oncol. 2016 Dec;11(12):2100-2111. doi: 10.1016/j.jtho.2016.09.121. Epub 2016 Sep 26.
10
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.贝伐珠单抗治疗新诊断的胸膜间皮瘤的 Mesothelioma Avastin Cisplatin Pemetrexed 研究(MAPS):一项随机、对照、开放标签、3 期临床试验。
Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21.

国际肺癌研究协会间皮瘤分期项目:即将发布的第九版胸膜间皮瘤 TNM 分类中“N”描述符的建议。

The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.

机构信息

Thoracic Surgery Department, Guy's Hospital, London, United Kingdom.

Department of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.

出版信息

J Thorac Oncol. 2024 Sep;19(9):1326-1338. doi: 10.1016/j.jtho.2024.05.003. Epub 2024 May 9.

DOI:10.1016/j.jtho.2024.05.003
PMID:38734073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11380593/
Abstract

INTRODUCTION

The International Association for the Study of Lung Cancer developed an international database to inform potential revisions in the ninth edition of the TNM classification of diffuse pleural mesothelioma (PM). This study analyzed the clinical and pathologic N categories to determine whether revisions were indicated relative to the eighth edition staging system.

METHODS

Of 7338 PM cases diagnosed from 2013 to 2022 and 3598 met all inclusion criteria for planned analyses. Data on 2836 patients without metastases were included in this study. Overall survival (OS) was measured from date of diagnosis. Patients were included regardless of whether they received neoadjuvant treatment. For the pathologic N analysis, patients who underwent resection (extrapleural pneumonectomy or pleurectomy/decortication) were included. N subgroups were analyzed and OS assessed by the Kaplan-Meier method.

RESULTS

The existing eighth edition N categories were performed adequately in the ninth edition data set. A median OS advantage was noted for clinical and pathologic N0 versus N1 patients: 23.2 versus 18.5 and 33.8 versus 25.0 months, respectively. Patients with resected pN0 had a 3-year OS of 48%. No difference in OS was noted for single- versus multiple-station nodal metastases. The number of nodal stations sampled at the time of resection was not associated with a difference in OS.

CONCLUSIONS

Data regarding clinical and pathologic N categories corroborate those used in the eighth edition. No changes in the N categories are recommended in the ninth edition of PM staging system.

摘要

简介

国际肺癌研究协会(IASLC)开发了一个国际数据库,旨在为第九版弥漫性胸膜间皮瘤(PM)的 TNM 分类修订提供信息。本研究分析了临床和病理 N 分期,以确定相对于第八版分期系统是否需要进行修订。

方法

在 2013 年至 2022 年间诊断的 7338 例 PM 病例中,有 3598 例符合计划分析的所有纳入标准。本研究纳入了 2836 例无转移的患者。总生存期(OS)从诊断日期开始计算。无论患者是否接受新辅助治疗,均纳入本研究。对于病理 N 分析,纳入接受了胸膜外全肺切除术或胸膜/肺切除术的患者。分析了 N 亚组,并通过 Kaplan-Meier 方法评估 OS。

结果

在第九版数据集的现有第八版 N 分期中表现良好。临床和病理 N0 与 N1 患者的 OS 优势明显:23.2 个月与 18.5 个月和 33.8 个月与 25.0 个月。接受根治性切除的 pN0 患者的 3 年 OS 为 48%。单一和多个淋巴结转移部位的 OS 无差异。在根治性切除时采样的淋巴结站数量与 OS 无差异。

结论

临床和病理 N 分期的数据与第八版使用的数据一致。在第九版 PM 分期系统中,不建议对 N 分期进行修改。